European CHMP recommends approval of inclisiran (Leqvio) for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia

Inclisiran reduces the intrahepatic PCSK9 enzyme and increases recycling of LDL-C receptor and its expression on the hepatocyte cell surface, thereby increasing LDL-C uptake and lowering LDL-C levels in the circulation. It will be available as a solution for injection.

Source:

European Medicines Agency